Solantic announces flu vaccination program
JACKSONVILLE, Fla. Solantic has announced the launch of its flu vaccination program for the 2010-2011 flu season at the company’s 34 walk-in urgent care centers statewide.
Solantic also provides offsite flu clinic services for those companies seeking to protect their employees.
The vaccine is priced at $30. Medicare and some insurance companies cover the cost of the flu shot. Solantic also offers the flu mist nasal spray for $40 and the pneumonia vaccine for $60.
The 2010-2011 seasonal flu vaccine will protect against three different flu viruses: an H3N1 virus, an influenza B virus and the H1N1 virus. Antibodies begin providing protection approximately two weeks after vaccination.
Allergan’s elevated intraocular pressure treatment gets nod from FDA
IRVINE, Calif. Allergan’s optimized reformulation of Lumigan has received approval from the Food and Drug Administration, the drug maker said Wednesday.
Lumigan 0.01% (bimatoprost ophthalmic solution) is a first-line therapy indicated for the reduction of elevated intraocular pressure with open-angle glaucoma or ocular hypertension, Allergan said. Lumigan 0.01% will be available in fourth quarter 2010 as the newest addition to Allergan’s comprehensive glaucoma portfolio.
"Lumigan 0.01% exemplifies Allergan’s commitment to developing medications for glaucoma patients that maximize efficacy while minimizing drug exposure,” said Scott Whitcup, Allergan’s EVP research and development and chief scientific officer.
Lilly’s Evista patents upheld in appeals court ruling
INDIANAPOLIS Eli Lilly’s method-of-use patents for its osteoporosis drug were declared valid by a federal court of appeals.
The drug maker said the Court of Appeals for the Federal Circuit has affirmed a prior ruling by the U.S. District Court for the Southern District of Indiana that the company’s patents for Evista (raloxifene HCl tablets) are valid.
“Protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve. We will continue to vigorously defend our rights, in order to support the development of the next generation of innovative medicines,” said Robert Armitage, SVP and general counsel for Lilly.